| Svetlana Reilly |
Cardiovascular Medicine |
Cardiovascular medicine |
Screening for hit compounds for the therapeutic purpose of treating cardiac fibrosis |
| Ben Davis |
Chemistry |
Anti-infectives |
Development of novel-mode anti-infectives |
| Gustavo Arruda Bezerra |
Nuffield Department of Medicine |
Anti-infectives |
Screening and characterization of small molecules targeting proteases for antibiotic development |
| Nicole Zitzmann |
Biochemistry |
Anti-infectives |
Towards a novel class of broad-spectrum antivirals |
| Shoumo Bhattacharya |
Wellcome Trust Centre for Human Genetics |
Cardiovascular medicine |
Evasins as chemokine traps for myocarditis |
| Claus Nerlov/Mario Buono |
Weatherall Institute |
Oncology |
Development of inhibitors targeting retrograde signalling in cancer |
| Irina Udalova |
Kennedy Institute |
Inflammation & Immunity |
Developing inhibitor tool compounds to investigate the IRF5 pathway and inflammation |
| Ivan Ahel |
Sir William Dunn School of Pathology |
Anti-infectives |
Development of potent antibacterials against a novel toxin-antitoxin system |
| Kristijan Ramadan |
Oncology |
Oncology |
Development of a first in class protease inhibitor in the field of oncology |
| Ming Lei |
Pharmacology |
Cardiovascular medicine |
Development of a small molecule kinase activator as a drug candidate for the management of heart failure and cardiac hypertrophy |
| Paul Brennan |
Nuffield Department of Medicine |
Oncology |
Inhibition of a Histone Methyl Transferase for the treatment of chemotherapy induced peripheral neuropathy |
| Beth Psaila/Adam Mead |
Weatherall Institute |
Oncology |
Megakaryocytes as novel cellular targets for myelofibrosis, a severe bone marrow disorder |
| David Vaux |
Sir William Dunn School of Pathology |
Neuroscience |
Amyloid oligomerisation inhibitors and microglial stabilisation |
| Cassandra Adams |
Nuffield Department of Medicine |
Musculoskeletal |
Pre-clinical development of a bromodomain inhibitor for the treatment of Dupuytren’s disease |
| Richard Williams |
Kennedy Institute |
Inflammation & Immunity |
Targeting the kynurenin pathway for the treatment of rheumatoid arthritis |
| Kim Midwood |
Kennedy Institute |
Inflammation & Immunity |
Targeting endogenous inflammatory triggers to treat chronic inflammation |
| Kilian Huber |
Nuffield Department of Medicine |
Oncology |
Identification of first-in-class small molecule inhibitors as potential immunooncology therapeutics |
| Yoshi Itoh |
Kennedy Institute |
Musculoskeletal |
Development of stereotactic modifiers selective for the collagenolytic activity of a protease |
| Mark Coles/Chris Buckley |
Kennedy Institute |
Inflammation & Immunity |
Inhibiting tissue damage in rheumatoid arthritis through a first in class therapeutic antibody |
| Alison Simmons |
Weatherall Institute |
Inflammation & Immunity |
Therapeutic targeting of a novel cytokine in Inflammatory Bowel Disease |
| George Tofaris |
Clinical Neurosciences |
Neuroscience |
Identification and development of novel PROTACs as a therapeutic strategy in Parkinson's disease |
| Monika Gullerova |
Pathology |
Oncology |
Identification of small molecules targeting the 53BP1 pathway as a new solution for PARPi resistance |
| Paul Brennan / Annette Von Delft |
NDM |
Oncology |
Pre-clinical development of a Histone Methyl Transferase Inhibitor for the treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN) |
| Krina Zondervan |
Nuffield Department of Women's and Reproductive Health |
Women's Health |
Pursuing a novel target in endometriosis |
| Deborah Goberdhan |
DPAG |
Oncology |
Selectively Reducing mTORC1-Mediated Growth by Transceptor Inhibition |
| Richard Wade-Martins |
DPAG |
Neuroscience |
High throughput screening by mass spectrometry for Friedreich's ataxia |
| Gillian Farnie |
NDORMS |
Oncology |
Development of a novel inhibitor for pre-clinical investigations in haematopoietic cancers |
| Ivan Ahel |
Pathology |
Oncology |
Discovery of inhibitors against a novel target to overcome PARPi resistance |
| Gustavo Arruda Bezerra |
NDM |
Metabolic disease |
Identification of novel inhibitors for the treatment of Classic Galactosemia |
| Mark Coles / Chris Buckley |
Kennedy |
Inflammation & Immunity |
Inhibiting the activation of pathogenic arthritic fibroblasts through a first-in-class inhibitor targeting a first-in-class ion channel |
| Liye Chen |
NDM |
Inflammation & Immunity |
Development of a novel inhibitor for pre-clinical investigations in inflammatory diseases |
| Christian Siebold |
NDM |
Oncology |
Development of novel inhibitors to overcome resistance mechanisms of existing anticancer therapies |
